Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia
Received 12 June 2020
Accepted for publication 6 August 2020
Published 3 September 2020 Volume 2020:14 Pages 1595—1604
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Johnny Chen
Alejandra Caqueo-Urízar,1 Alfonso Urzúa,2 Patricio Mena-Chamorro,3 Guillaume Fond,4 Laurent Boyer4
1Instituto de Alta Investigación, Universidad de Tarapacá, Arica, Chile; 2Escuela de Psicología, Universidad Católica del Norte, Antofagasta, Chile; 3Escuela de Psicología y Filosofía, Universidad de Tarapacá, Arica, Chile; 4Aix-Marseille Univ, EA 3279 – Public Health, Chronic Diseases and Quality of Life - Research Unit, Marseille 13005, France
Correspondence: Alejandra Caqueo-Urízar
Instituto de Alta Investigación, Universidad de Tarapacá, Antofagasta 1520, Arica, Chile
Purpose: The purpose of this study was to describe the association between adherence to antipsychotic medication and quality of life (QoL) in a sample of individuals diagnosed with schizophrenia.
Methods: Two hundred fifty-three patients were included from three public mental health services from Bolivia, Peru, and Chile. Data were collected using the Drug Attitude Inventory (DAI-10) and the Schizophrenia Quality of Life short-version questionnaire (SQoL-18), which considers 8 dimensions.
Results: Significant associations were found between adherence to antipsychotic medication treatment and QoL (S-QoL-18 index: β = 0.26, p = 0.004; self-esteem: β = 0.37, p = 0.000; and sentimental life: β = 0.20, p = 0.033). Associations of clinical and socio-demographic variables with QoL were identified: severity of psychotic symptoms, awareness of the disease, gender, age, and ethnicity were found to be associated with a lower level of QoL (β from 0.14 − 0.56).
Conclusion: This study provides evidence of the association between adherence to treatment and quality of life in patients diagnosed with schizophrenia. Therefore, as in developed countries, improving adherence to antipsychotic medication would appear to be an important issue to address to improve patients’ QoL in Latin American countries.
Keywords: adherence, quality of life, schizophrenia, Latin-American
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]